Cargando...
Glecaprevir/pibrentasvir-associated acute liver injury in non-cirrhotic, chronic HCV infection without HBV co-infection
The combination of glecaprevir and pibrentasvir was recently approved for chronic hepatitis C virus (HCV) infection with recommended treatment duration of 8–12 weeks depending on previous treatments, viral genotype and cirrhosis status. Although liver injury was reported with other protease inhibito...
Guardado en:
| Publicado en: | BMJ Case Rep |
|---|---|
| Autores principales: | , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
BMJ Publishing Group
2019
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6536190/ https://ncbi.nlm.nih.gov/pubmed/31129632 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bcr-2018-226622 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|